A group of actors, including Benedict Cumberbatch and Benedict Wong, have publicly opposed the proposed $110 billion takeover of Warner Bros by Paramount-Skydance. Their concerns, voiced in an opinion piece, focus on the potential ramifications for global filmmaking, news production, and the UK's creative sector.
This intervention stands out as political statements from entertainment figures are often overlooked. However, the prominence of the actors involved and the widespread familiarity with film and television have allowed this particular deal to garner significant media attention. This attention contrasts with a broader trend over the first half of the year, which saw a record $231 billion in British companies, including those in critical sectors like technology, AI, and pharmaceuticals, acquired by overseas buyers, often financed by private equity firms.
Notable acquisitions include the ongoing merger talks between Britain's ITV and Comcast, the owner of Sky and Universal. Additionally, Segro, the UK's largest data center operator, is set to be acquired by San Francisco-based Prologis. Pinewood Technologies, a service provider to the automotive industry, is also facing a bid from American private equity firm Ridgeview. The author argues that while these deals may appear less glamorous than entertainment acquisitions, they can still lead to job losses, loss of control, and reduced UK tax revenues.
The Paramount-Warner deal, which has reportedly attracted the attention of UK Culture Secretary Lisa Nandy, could impact jobs within Britain's creative sector, which supports over 180,000 people and generates approximately £6.8 billion in production spending. Concerns have also been raised that CNN, known for its critical stance on political figures, might be influenced by the leanings of Larry Ellison, a financier of the Paramount bid.
The article also points to Comcast's prior acquisition of Sky, which resulted in significant write-offs and the dismantling of certain Sky divisions. Questions remain about the future of Sky News and ITN in light of this ongoing transaction, despite reported favorable views in Whitehall due to Universal's planned investment in a theme park.
Separately, AstraZeneca CEO Pascal Soriot has sought to reassure investors following recent setbacks with two drug candidates. The company reported better-than-expected second-quarter earnings and reaffirmed its income forecast of $80 billion by 2030, leading to a rise in its shares. AstraZeneca's focus has shifted towards the U.S. market, with efforts to secure a higher valuation and a New York listing. Despite clinical challenges, the approval of its breast cancer medicine Etcamah by the European Drugs Agency, developed in Cambridge, underscores the continued strength of British pharmaceutical research and development.